Access
Home
Search
Monetization
Profile
Cardiac Biomarkers Market Size and Share By Industry Demand, Worldwide Research, Prominent Players, Emerging Trends, Investment Opportunities
Your avatar
SA
by
saurabhrj
Your avatar
SA
by
saurabhrj
Cardiac Biomarkers Market Size and Share By Industry Demand, Worldwide Research, Prominent Players, Emerging Trends, Investment Opportunities

The global “cardiac biomarkers market” size is expected to reach USD 26.33 billion by 2027, exhibiting a CAGR of 11.2% during the forecast period. The growing incidence of critical cardiac conditions, including myocardial infarction, heart attack, and acute coronary syndrome (ACS) will subsequently inflate demand for cardiac biomarkers in the forthcoming years, mentioned in a report, titled “Cardiac Biomarkers Market Size, Share & Industry Analysis, By Indication (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, and Others), By Biomarker (Troponin, Creatine kinase-MB (CK-MB), B-type Natriuretic Peptide (BNP), Myoglobin, and Others), By End User (Hospitals, and Specialty Clinics), and Regional Forecast, 2020-2027” the market size stood at USD 13.15 billion in 2019. The increasing prevalence of cardiovascular diseases will spur opportunities for the market during the forecast period.

Get Request a Sample Copy of the Cardiac Biomarkers Report:

https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/cardiac-biomarkers-market-101233

Major Cardiac Biomarkers Market Key players covered in the report include:

Thermo Fisher Scientific

Abbott

Becton

Bio-Rad Laboratories, Inc.

F. Hoffmann-La Roche Ltd.

Randox Laboratories Ltd.

Beckman Coulter, Inc.

Dickinson and Company

Dickinson and Company

bioMérieux SA

Other key market players

Cardiac Biomarkers Market Analysis 2021:

Market Driver:

Cardiovascular Interventions to Promote Biomarkers Adoption

The increasing R&D investments by key players for the introduction of robust and novel cardiac biomarkers to benefit patients in diagnosis, prognosis and predictive analysis of cardiovascular disorders will enable speedy expansion of the market. The innovation in clinical cardiology and cardiovascular interventions can be an essential factor in fostering the growth of the market. Moreover, the increasing product launches by key players will augur well for the market in the forthcoming years. For instance, In July 2018, Siemens announced that it has received the U.S. Food and Drug Administration (FDA) approval for high-sensitivity troponin I assays (TnIH). The test will be beneficial in the early diagnosis of myocardial infarctions without the need for serial tropic testing. Similarly, in September 2019, Abbott unveiled ARCHITECT STAT High Sensitivity Troponin-I blood test after receiving the approval from the U.S. Food and Drug Administration (FDA) approval. The test will help in detecting heart attacks in real-time, and more accurately than contemporary troponin tests.

0.00€
Cheer up, leave your comment
0
If you liked this post, you may also be interested in...
O
© 2021, Mamby Investments
Information Work with us Terms and Conditions Contact FAQs